WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced data demonstrating early clinical signs of potential anti-metastatic activity observed with ARQ 197, the Company’s selective, small molecule inhibitor of the c-Met receptor tyrosine kinase, as well as data showing a reduction in metastases in animal models treated with this compound.
